OBJECTIVES: Maternal Death (MD) is a health public issue in Mexico, the MD Ratio (MDR) is 43.2 deaths/100,000 newborns, the Post-Partum Hemorragea (PPH) represents the second cause of MD (23%), with a higher impact in mexican provinces with poor or limited  blood products access. The purpose of this study was to estimate from the health service provider perspective, the cost-effectiveness in the use of Human Fibrinogen (HF) (Clottafact^®) in the hematologic treatment of masive PPH during limited access of boold products (access after 20 minutes). METHODS: A decition tree was created to estimate the survival probabilities and costs of PPH under a limited blood product access scenario, the use of HF or the use of  recombinant Factor VII alfa (Factor rVIIa). The effectiveness was obtained from literature. The costs were estimated throughout an expert consensus and were expressed in US Dollars (exchange rate 1USD/13.0 MXN). The CER and ICER were estimated per saved live and a probabilistic sensibility analysis was performed. RESULTS: The average cost per treated patient with limited access to blood products was 12,350 USD, with HF was $13,182 USD wheras with Factor rVIIa it was $14,526 USD. The survival rate was 0.59, 0.98 and 0.93 respectively. The cost per saved life with limited treatment was $21,238 USD, with HF was $13,410 and with Factor rVIIa it was $15,552 USD. The acceptability curve shows that the use of HF is cost-effective in 65% to 85% of the cases with a $3,000 USD willingness to pay limit. CONCLUSIONS: Human Fibrinogen represents the best treatment alternative for the PPH in Mexican provinces with poor access to blood products and it would significantly reduce the MDR in Mexico.